Skip to main content
Clinical Trials/EUCTR2019-001997-27-CZ
EUCTR2019-001997-27-CZActive, not recruitingPhase 1

Rationalisation of ATB therapy in diabetic foot infection and its impact on the intestinal microbiota - DFIATIM

Institut klinické a experimentální medicíny0 sites60 target enrollmentStarted: June 4, 2019Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Patients included into the study should fullfil the following criteria:
  • -Patients with Type 2 diabetes mellitus and DF infection (DF ulcers of Texas 2-3/B or D) indicated for i.v. ATBs (ceftazidime or amoxicillin/clavulanic acid)
  • -Positive tissue culture
  • -Signed Informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 45
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 15

Exclusion Criteria

  • Patients who fullfilled one of these criteria will be excluded:
  • Severe hepatic insufficiency, chronic renal insufficiency/failure – stage 4-5 based on the Chronic Kidney Disease (CKD) classification, severe malnutrition, indication for emergent foot amputation, recent percutaneous transluminal angioplasty (within 2 weeks), indication for acute revascularisation with regard to rapid progression of PAD or acute arterial ischaemia, allergy to test ATBs, presence of a diagnosed neoplasm, pregnancy, lactation, septic shock, active Ebstein-Barr virus, Inflammatory Bowel Disease (IBD), coeliac disease or any other malabsorption disease, acute gastroenteritis.

Investigators

Similar Trials